Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807107 | 0.89 | SMN1; SMN2 (0.55) | KMT2ALMNASMN1; SMN2MEN1KDM4E | |
| SCHEMBL2265144 | 0.88 | MAPK1 (0.54) | KMT2ALMNASMN1; SMN2MEN1EPHX2 | |
| SCHEMBL2259603 | 0.86 | KDM4E (0.54) | KMT2ALMNAEPHX2MAPK1KDM4E | |
| SCHEMBL22807113 | 0.77 | KMT2A (0.52) | KMT2ALMNASMN1; SMN2MEN1KDM4E | |
| SCHEMBL14503836 | 0.76 | SMN1; SMN2 (0.51) | KMT2ALMNASMN1; SMN2MEN1KDM4E | |
| SCHEMBL2264334 | 0.74 | MAPT (0.57) | KMT2ALMNASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL901378 | 0.72 | LMNA (0.66) | KMT2ALMNASMN1; SMN2MEN1KDM4E | |
| SCHEMBL2240205 | 0.72 | HTR1A (0.50) | KMT2A | |
| SCHEMBL3026440 | 0.72 | L3MBTL1 (0.45) | KMT2ASMN1; SMN2MEN1EPHX2MAPK1 | |
| SCHEMBL3783886 | 0.72 | RORC (0.40) | KMT2AEPHX2MAPK1KDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | KMT2A 938/4885LMNA 2667/4885SMN1; SMN2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.